Clinical Trial Update: Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd

View source ↗

Summary

Real-world study evaluating post-resistance treatment strategies after CDK4/6 inhibitors, PIK3CA inhibitors, or trastuzumab deruxtecan in advanced/metastatic br…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Abemaciclib (abemaciclib)
• Alpelisib (alpelisib)
• Palbociclib (palbociclib)
• Ribociclib (ribociclib)
• Trastuzumab deruxtecan (trastuzumab deruxtecan)

Snippet

Sponsor: Hunan Cancer Hospital | Conditions: Metastatic Breast Cancer, Drug Resistance | Status: RECRUITING